Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 113 for your search:
Cancer Type/Condition:
Brain tumor, adult: Astrocytoma/Astrocytic tumors
Stage/Subtype:
anaplastic astrocytoma, adult
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Low-dose Temozolomide for 2 Weeks on Brain Tumor (Study P04602AM1)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P04602
, NCT00424554
2.
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MRC-BR12
, EU-20114, ISRCTN83176944, NCT00052455
3.
Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-26053
, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, NCT00626990
4.
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP 12009-G005
, NCT00761280
5.
Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0577
, N0577, NCT00887146
6.
Treatment Strategy for Low-Grade Gliomas
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
YP2008009
, NCT00897377
7.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
8.
ZD6474 in Treating Patients With Recurrent or Progressive Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0063
, NCI-P6680, NCT00293566
9.
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
501007705
, NCT00301418
10.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
11.
Radiosurgery for Glioblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 65
Sponsor:
Other
Protocol IDs:
2006P-000464
, NCT00456612
12.
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
13.
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NU07C1
, NU 07C1, NCT00516282
14.
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
REO 007
, NCT00528684
15.
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N057K
, N057K, NCT00553150
16.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
17.
BSI-201 and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
ABTC-0703
, NABTT-0703, NABTT-0703, NCT00589576
18.
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
05-115
, RO1 NS055140, NCT00766753
19.
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-342
, CLBH589BUS42T, NCT00859222
20.
Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 64
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
NPC-08-1
, NCT00919737
21.
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
00016446
, NCT00939991
22.
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
3 to 25
Sponsor:
NCI, Other
Protocol IDs:
CDR0000437085
, SJCRH-SJHG04, GENENTECH-OSI3160s, NCT00124657
23.
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Phase:
Phase II, Phase I
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
EH09-377
, NCT00977795
24.
Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate With or Without Sodium Thiosulfate in Treating Patients With High-Grade Glioma
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-7328
, OHSU-922, OHSU-ONC-02059-L, NCT00075387, CASE-CCF-6385
25.
Tamoxifen and Bortezomib in Treating Patients With Recurrent Gliomas
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-05-C-0137
, NCT00112762
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
